At age 58, women with Alzheimer's disease declined an average of 29 percent more each year in global cognition than white men, according to Alzforum. This rapid deterioration occurs despite women often starting with superior global cognition and executive function. Their initial cognitive advantage may mask a more aggressive disease progression, leading to a significantly steeper and faster decline after an Alzheimer's diagnosis.
Without targeted research and sex-specific treatment approaches, women will continue to bear a disproportionate and accelerated burden of Alzheimer's disease. Current therapies may fall short for the majority of patients.
The Disproportionate Toll on Women
- Two-thirds of people living with Alzheimer's disease are women, according to PMC.
- Women face steeper rates of cognitive decline after an Alzheimer's diagnosis compared to men, states PMC.
This staggering number of affected women, coupled with their accelerated decline, creates a critical public health crisis. It demands focused attention on sex-specific disease mechanisms.
Unpacking the Biological Differences
Having one copy of the APOE ε4 allele increases the risk for developing Alzheimer's disease up to four times higher in women compared to men aged 65–75, reports PMC. This genetic factor plays a significantly more detrimental role in women. Yet, memory declined at the same rate in both sexes, according to Alzforum. This reveals Alzheimer's progression manifests differently in women, impacting specific cognitive domains more severely. Distinct biological pathways for disease progression warrant deeper investigation.
The Research Blind Spot
Recent reviews show only 12.5% of randomized clinical trials for AD drugs evaluate results specifically in women, according to PMC. This severe underrepresentation means current and future treatments may not be optimized for them. Women comprise two-thirds of Alzheimer's patients and experience a 29% faster annual decline in global cognition. Yet, the medical community's failure to evaluate results specifically for women in 87.5% of clinical trials represents a profound ethical and scientific oversight.
If research and clinical trials continue to overlook sex-specific differences, treatments for Alzheimer's disease will likely remain suboptimal for the majority of women, perpetuating a significant health disparity.
